Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.69% is 193% above its 5-year average of 6.04%, near the low end of its 5-year range (0.00%–154.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.33% below its 12-month average of 19.09%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.69%.
DEBT TO ASSETS RATIO
17.69%
DEBT TO ASSETS RATIO AVG TTM
19.09%
DEBT TO ASSETS RATIO AVG 3Y
8.74%
DEBT TO ASSETS RATIO AVG 5Y
6.04%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-7.33%
CURRENT VS 3Y AVG
+102.48%
CURRENT VS 5Y AVG
+192.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 866 covered companies
CURRENT VS SECTOR MEDIAN
+19555.71%
vs the sector median at left
MoonLake Immunotherapeutics
Market Cap
$927.47M
Debt to Assets Ratio
17.69%
TTM Avg
19.09%
3Y Avg
8.74%
5Y Avg
6.04%
Market Cap
$939.11M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$913.78M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$946.27M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$891.94M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$966.09M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $927.47M | 17.69% | 19.09% | 8.74% | 6.04% |
| CeriBell, Inc. (CBLL)vs › | $932.06M | 0.13% | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $939.11M | 0.04% | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $913.78M | 0.03% | N/A | N/A | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $946.27M | 0.01% | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $948.81M | 0.16% | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $899.02M | 0.39% | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $891.94M | 0.05% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $966.09M | 0.02% | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 0.33% | N/A | N/A | N/A |
Debt/Assets
17.7%
Debt/Equity
0.24
Current Ratio
12.56
Interest Coverage
-33.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.69% |
| 2026-03-31 | 25.18% |
| 2025-12-31 | 17.84% |
| 2025-09-30 | 18.28% |
| 2025-06-30 | 16.47% |
| 2025-03-31 | 14.79% |
| 2024-12-31 | 0.59% |
| 2024-09-30 | 0.71% |
| 2024-06-30 | 0.61% |
| 2024-03-31 | 0.65% |
| 2023-12-31 | 0.70% |
| 2023-09-30 | 0.03% |
| 2023-06-30 | 0.04% |
| 2023-03-31 | 0.37% |
| 2022-12-31 | 0.37% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 6.55% |
| 2021-12-31 | 154.92% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.05% |
